Patients were randomized to receive ranibizumab on day @ , month @ , and thereafter as needed guided by VA stabilization criteria ( group I , n = @ ) ; ranibizumab on day @ and thereafter as needed guided by disease activity criteria ( group II , n = @ ) ; or vPDT on day @ and disease activity treated with ranibizumab or vPDT at investigators ' discretion from month @ ( group III , n = @ ) .